Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma

Sayo Kobayashi, Kazuhiro Nouso, Hideaki Kinugasa, Yasuto Takeuchi, Takeshi Tomoda, Koji Miyahara, Hiroaki Hagihara, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Fusao Ikeda, Yasuhiro Miyake, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Aim: Hepatocellular carcinoma (HCC) is a common clinical problem all over the world. Fucosylated hemopexin (Fuc-Hpx) is a newly reported glycoprotein for the diagnosis of HCC, however, its clinical implications are unclear. The aim of this study was to elucidate the clinical utility of Fuc-Hpx in Japanese patients with HCC. Methods: The sera from 331 HCC patients, 45 with liver cirrhosis (LC), 85 with chronic hepatitis (CH) and 22 healthy people were examined for the expression of Fuc-Hpx; the level was compared with clinical parameters as well as hemopexin (Hpx) expression. The expressions of Fuc-Hpx in 12 HCC tissues and corresponding adjacent non-cancerous liver tissues were also examined. Results: No correlation was observed between Hpx and Fuc-Hpx level. The median Fuc-Hpx levels in healthy people and CH, LC and HCC patients were 3.8, 3.7, 6.1 and 7.6AU/mL, respectively (CH vs LC, P=0.002; CH vs HCC, P<0.001; LC vs HCC, P=0.02). Multivariate analysis revealed that low albumin, low prothrombin time and the presence of HCC were significantly correlated with high Fuc-Hpx (P=0.013, =0.001 and <0.001, respectively). Among the HCC patients, albumin was correlated with high Fuc-Hpx; however, none of the tumor factors, such as tumor size, tumor number and tumor stage, was correlated with Fuc-Hpx level. The expression of Fuc-Hpx in cancer tissue was not different from that in non-cancerous tissue. Conclusion: Fuc-Hpx is a valuable biomarker for HCC but it might be a marker for hypercarcinogenic liver rather than a marker for tumor-bearing liver.

Original languageEnglish
Pages (from-to)1187-1195
Number of pages9
JournalHepatology Research
Issue number12
Publication statusPublished - Dec 2012


  • Biomarker
  • Fucosylated hemopexin
  • Glycosylation
  • Hepatocellular carcinoma
  • Hypercarcinogenicity

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases


Dive into the research topics of 'Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this